Compare Jones Lang LaSalle Inc (JLL) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.58B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| JLL | KYMR | |
|---|---|---|
Market Cap | $13.58B | $8.88B |
Volume | 414,312 | 1,028,790 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $127.31 |
52-Week Low | $280.16 | $55.80 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.34B | $8.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $298.32, up 0.07% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 14.16 and P/S of 0.51, alongside consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M. Recent news highlights acquisitions and positive growth coverage, while analyst consensus is bullish with a $450.50 price target.
The outlook for JLL is positive based on earnings momentum and attractive valuation, though near-term technical weakness and reliance on real estate market cycles present risks. Upside potential exists if the company maintains its earnings beat streak and capitalizes on data center and global real estate growth trends highlighted in recent analyst reports.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
